@ancoraai
Ancora.ai is an AI-enabled digital platform that enables cancer patients & their care teams to find trials. We believe technology can help improve access and make clinical trial recruitment more efficient. Check out the tool at www.ancora.ai
Wonderful to see @braintumor.org launch their new #AI Clinical Trial Finder, proudly powered by @ancoraai.bsky.social
#NBTS's Clinical Trial Finder tool helps match #braintumor patients to relevant #clinicaltrials in seconds.
Explore this free resource to know your options: BrainTumor.org/Trials
📌NEW VIDEO: Clinical trials related to #pheochromocytoma and #paraganglioma.
📱Watch Dr. Justin Annes presenting an overview of the specifics in diagnostics and treatment of #pheochromocytoma and #paraganglioma, and the ongoing clinical trials: incalliance.org/dr-justin-an...
#LetsTalkAboutNETs
As the year ends, we’re filled with gratitude 💫
Thank you to our patients for your trust in Ancora.ai 🙏
To our partners & sponsors: thank you for your collaboration & support in keeping the Ancora.ai Trial Finder tool free & accessible for all 👏
Wishing you all a peaceful holiday season!
Congrats!
For the UK #neuroendocrinecancer community, please help Neuroendocrine Cancer UK with this survey:
lnkd.in/efPpvrga
By completing this survey, you will help shape the UK’s future neuroendocrine cancer research agenda & ensure that questions most important to patients, families & clinicians are heard
📌The specifics of neuroendocrine carcinoma were discussed by NET experts and patients at the @enets.org & INCA NET Cancer Day 2025 Educational Webinar.
📱Now you can watch the recording at your own pace: incalliance.org/the-recordin...
#LetsTalkAboutNETs
📌The #ThinkNENs program is designed to empower PCPs with the knowledge to recognize NENs and refer NEN patients earlier.
• Free, online & CME-accredited
• Available in 7 languages
• Endorsed by top NEN societies
✅Start today: incalliance.org/think-nens/
#LetsTalkAboutNETs
Huge thanks to patient orgs like @netrf.org and @inca-netcancerday.bsky.social for their incredible work driving #patient awareness of trials!
We must ensure their efforts don't go unanswered.
#ClinicalTrials #DigitalHealth #PatientAdvocacy #patientrecruitment #healthequity
The challenge isn't lack of interest; it's a breakdown in execution. We must do better.
📣Call to Action for Sponsors, Sites & Research Institutions:
We need to redesign & modernize patient recruitment pathways. Let's work together to fix this systemic leak & ensure every patient connection counts.
This isn't just a #NET issue- across 17 countries (2021-24):
📈 High Interest: 91% of cancer patients want to participate (CISCRP).
📉 Severe Leak: Only 20% of interested cancer patients actually get the timely, actionable info needed for a referral.
#patientrecruitment #clinicaltrials
🚨 The Leak is REAL.
Our analysis showed a staggering 78% of patient trial requests received NO response from sites OR were for trials that were already closed.
We called this the "Last Mile Leak" with Ken Getz from Tufts CSDD: bit.ly/3KnXcNm
#patientrecruitment #clinicaltrials
💡 Just presented our abstract at the @netrf.org Medical Symposium 2025!
Our data from the ancora.ai #NET Digital Trial Finder exposed a critical breakdown in patient recruitment.
The issue? Patient interest is strong, but the follow-up process is failing them.
#ClinicalTrials #NeuroEndocrineTumors
And a huge thank you for the opportunity to showcase our poster on how ancora.ai's tech can effectively identify #clinicaltrials for #CUP patients & expand treatment options.
Congratulations to the World CUP Alliance on a successful inaugural event & a great kick off to
@myesmo.bsky.social
There were many discussions on:
-better segmenting #CUP patients
-quickly & effectively identifying a primary to get to targeted therapies
-challenges of accessing targeted therapies
The future lies in multi-omics, adv. imaging (incl. #radiopharmaceuticals), liquid biopsies & global collaboration.
Ancora.ai was honored to have attended the 1st-ever World #CUP Alliance meeting yesterday in Berlin!
The meeting was an inspiring day full of incredible research & collaboration focused on improving the lives of patients with Cancer of Unknown Primary (CUP).
#cancerunknownprimary
ICYMI: @danafarber.bsky.social's Patrick Wen, MD, spoke with @oncodaily.bsky.social On Air about the @fda.gov approval of Dordaviprone in H3K27M-mutated diffuse midline glioma.
Listen here: bit.ly/3KqeLMk
Please reach out if you'd like to learn more or help us amplify this important resource for patients and their care teams.
#cancerresearch #clinicaltrials #cancer #braincancer #GBM #gliomas #meningioma #medulloblastoma
Our #braintumor #clinicaltrial finder tool is now live!
A huge thanks to our incredible expert group of #patient advocates, #physicians, researchers & #biotech as well as our collaborators 5P Health Care Solutions.
Link to tool www.ancora.ai/braintumors
Press release www.ancora.ai/en/newsartic...
Do you know how easy it is to quickly find a NEN clinical trial that fits your condition and is close to your location?
✅Try here: incalliance.org/find-a-trial/
#LetsTalkAboutNETs #NENClinicalTrials
@ancoraai.bsky.social
A heartfelt thank you to our users for your engagement and feedback. In just 6 months we've had users from 28 countries use our radtrials.com tool!
Next up: We're looking forward to #ASCO2025 and #SNMMI2025 so please be sure to say hello!
#clinicaltrials #cancerresearch #Cansky #Oncsky #Medsky
#ICPO2025 brought together leading minds from across the world, sparking insightful discussions around the implementation & personalization of #radiopharamceuticals in #cancer.
And if you haven't heard of radiopharmaceuticals or #nuclearmedicine, be sure to check out @nucmed-patients.bsky.social
Our team was privileged to attend ICPO Foundation's forum- a fantastic gathering focused on the advancement of #radiopharmaceuticals in #oncology.
We're grateful for the opportunity to have presented our newly released Global Radiopharmaceutical Trial Finder powered by Ancora.ai
💫 www.radtrials.com
1/3 Excited to share two recent publications! 🧠💡 First, we explored radioligand target expression in high-grade #meningioma, finding #SSTR2a and #FAP variably expressed, with implications for patient selection and radioligand therapy design. @nathaliealbert.bsky.social doi.org/n786
Do you want to know what is happening in radioligand therapy for patients with neuroendocrine tumors? What is hot and what is not...? if so this team (which has not yet migrated over to BlueSky...) has you covered... 😀
onlinelibrary.wiley.com/doi/10.1111/...
❤️
Patient advocate @sunonmyhip.bsky.social joins #LungCancerConsidered host @narjustflorezmd.bsky.social to discuss her lung cancer journey & the power of advocacy groups. Learn about self-advocacy, patient-centered care & palliative care.
🎧 Listen now: bit.ly/PAGroups
#PatientAdvocacy
Photo of Dr Naidoo on stage
Dr Naidoo presenting conclusions
Compares future to various movies
Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM
Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy.
🔬 The results of #COMPETE trial were presented today by Jaume Capdevila, at the 22nd Annual Conference of #ENETS 👉 https://linke.to/COMPETEVHIO
David James spoke to Anna Jones at
@skynewsrss.bsky.social this morning with patient advocate Dee to discuss why we need urgent reform in how we diagnose prostate cancer. Too many men are being diagnosed too late - we must act now. It's time for a screening programme
www.youtube.com/watch?v=CdUB...
Winn Excellence in Clinical Trials Program
The Winn Career Development Award is open for applications! The 2-year program provides training and support for early-stage investigator physicians to improve participation in clinical trials. Details at winnawards.org. Apply by May 12, 2025. #WinnAwards #WinnCDA @drdonsdizon.bsky.social